{"classes":[{"categories":[{"measurements":[{"comment":"Here, \"NA\" signifies that median, lower and upper limit of 90% CI were not estimable due to low number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Here, \"NA\" signifies that median and upper limit of 90% CI were not estimable due to low number of participants with events.","groupId":"OG001","lowerLimit":"59.9","upperLimit":"NA","value":"NA"},{"groupId":"OG002","lowerLimit":"40.4","upperLimit":"80.3","value":"76.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"23"}],"units":"Participants"}],"description":"Time to next treatment (TNT) for active myeloma were reported. Time to next treatment was defined as the time from the date of randomization to the date of the first subsequent multiple myeloma treatment. Kaplan-Meier estimate was used.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received daratumumab 16 milligrams per kilogram (mg/kg) as intravenous (IV) infusion once every week (Q1W) (Days 1, 8, 15, 22, 29, 36, 43 and 50) in Cycle 1, every other week (Q2W) (Days 1, 15, 29 and 43) in Cycle 2 and 3, every 4 weeks (Q4W) (Days 1 and 29) in Cycle 4 to 7, and on Day 1 from Cycle 8 to 20. Each treatment cycle was of 8 weeks. After Cycle 20, per investigator's discretion, participants either entered into extension phase or completed end of treatment visit 4 weeks after last dose. In extension phase, participants continued to receive daratumumab 16 mg/kg as IV infusion every 8 weeks (Q8W), after end of Cycle 20 up to 91.6 months, and then completed end of treatment visit 4 weeks after last dose. After protocol amendment 5, participants in extension phase optionally switched to daratumumab 1800 mg subcutaneous (SC) Q8W per investigator's discretion. After end of treatment, participants were followed up for safety until death, lost to follow up, consent withdrawal/study end, whichever occurred first (up to 7.89 years).","id":"OG000","title":"Arm A (Long Intense)"},{"description":"Participants received daratumumab 16 mg/kg as IV infusion Q1W (Day 1, 8, 15, 22, 29, 36, 43 and 50) in Cycle 1, and then on Day 1 of each cycle from Cycle 2 to Cycle 20, and Q8W after Cycle 20. Each treatment cycle was of 8 weeks. After Cycle 20, per investigator's discretion, participants either entered into extension phase or completed end of treatment visit 4 weeks after last dose. In extension phase, participants continued to receive daratumumab 16 mg/kg as IV infusion Q8W after end of Cycle 20 up to 91.6 months, and then completed end of treatment visit 4 weeks after last dose. After protocol amendment 5, participants in extension phase optionally switched to daratumumab 1800 mg SC Q8W per investigator's discretion. After end of treatment, participants were followed up for safety until death, lost to follow up, consent withdrawal/study end, whichever occurred first (up to 7.89 years).","id":"OG001","title":"Arm B (Intermediate)"},{"description":"Participants received daratumumab 16 mg/kg as IV infusion Q1W (Day 1, 8, 15, 22, 29, 36, 43 and 50) in Cycle 1 alone. Treatment cycle was of 8 weeks. After Cycle 1, participants completed the end of treatment visit 4 weeks after last dose and were followed up for safety until death, lost to follow up, consent withdrawal, or study end, whichever occurred first (up to 7.89 years).","id":"OG002","title":"Arm C (Short Intense)"}],"paramType":"MEDIAN","populationDescription":"ITT analysis set was defined as participants who were randomly assigned to one of the 3 daratumumab schedules based on IWRS. Here \"N\" (Overall number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From randomization (Day -5) up to the date of first subsequent antimyeloma treatment (up to 7.89 years)","title":"Time to Next Treatment (TNT) for Active Myeloma","type":"SECONDARY","unitOfMeasure":"months"}